Profile data is unavailable for this security.
About the company
Karolinska Development AB is a Sweden-based investment company. The Company provides capital to biotechnology firms, as well as develops and commercializes biotechnological products. Its activities are involved in a range of areas: oncology, infections and wound healing, women’s health, cardiovascular and hematology, medical equipment, diagnostics, pharmaceutical formulation, as well as implants, among others. The Company’s pharmaceuticals portfolio comprises: AXL1717 for non-small-cell lung carcinoma (NSCLC), APR-246 for ovarian cancer, Sevuparin for malaria, SHACT for pain relief at hysteroscopy and intrauterine device (IUD) insertion, and PC-mAB for acute coronary syndrome (ACS), among others. Furthermore, the Company controls a number of subsidiaries, such as Avaris AB, HBV Thernostica AB, KD Incentive AB, KDev Oncology AB and Limone AB.
- Revenue in SEK (TTM)1.94m
- Net income in SEK33.61m
- Incorporated2006
- Employees8.00
- LocationKarolinska Development ABTomtebodavagen 23 ASOLNA 171 65SwedenSWE
- Phone+46 852486070
- Websitehttps://www.karolinskadevelopment.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SpectraCure AB (publ) | 2.84m | -20.44m | 310.82m | 15.00 | -- | 2.39 | -- | 109.33 | -0.2104 | -0.2104 | 0.0293 | 1.34 | 0.0185 | -- | 17.28 | 189,533.30 | -13.31 | -12.75 | -14.35 | -13.62 | 435.56 | 195.30 | -718.99 | -494.40 | -- | -- | 0.0492 | -- | -3.30 | -- | 19.46 | -- | -- | -- |
Scandinavian Medical Solutions A/S | 298.59m | 19.09m | 330.72m | -- | 17.19 | 2.83 | 12.20 | 1.11 | 0.4479 | 0.4479 | 7.00 | 2.73 | 1.42 | 2.00 | 17.46 | -- | 9.05 | -- | 15.48 | -- | 25.83 | -- | 6.39 | -- | 0.4062 | 19.96 | 0.2776 | -- | 72.98 | -- | 7.49 | -- | -- | -- |
Micropos Medical AB (publ) | 1.64m | -23.54m | 367.66m | 4.00 | -- | 39.59 | -- | 224.46 | -0.1663 | -0.1663 | 0.0117 | 0.0611 | 0.0606 | 0.0538 | 1.46 | -- | -87.07 | -64.24 | -115.32 | -82.27 | 86.75 | 114.76 | -1,437.12 | -767.58 | 1.15 | -- | 0.0429 | -- | 50.24 | 5.94 | -26.57 | -- | -- | -- |
Boule Diagnostics AB | 571.33m | 25.08m | 388.33m | 228.00 | 15.70 | 0.8174 | 7.42 | 0.6797 | 0.6368 | 0.6368 | 14.64 | 12.23 | 0.7542 | 4.67 | 3.84 | 2,505,829.00 | 3.28 | 1.67 | 4.48 | 2.40 | 43.69 | 43.50 | 4.35 | 2.04 | 1.07 | 4.27 | 0.2591 | 42.24 | 4.24 | 6.13 | 96.24 | -9.45 | -9.74 | -- |
Karolinska Development AB | 1.94m | 33.61m | 422.69m | 8.00 | 12.69 | 0.3419 | 12.26 | 218.22 | 0.1245 | 0.1245 | 0.0072 | 4.62 | 0.0016 | -- | 1.66 | 242,125.00 | 2.71 | 3.37 | 2.73 | 3.83 | -- | -- | 1,734.95 | 1,466.36 | -- | -- | 0.0023 | 0.00 | -12.43 | -8.10 | 106.11 | -29.31 | -- | -- |
Modulight Oyj | -1.16tn | -1.16tn | 436.22m | 70.00 | -- | 0.6957 | -- | -- | -- | -- | -- | 1.26 | -- | -- | -- | -- | -- | -8.39 | -- | -9.10 | -- | 114.69 | -- | -56.81 | 6.11 | -- | 0.1004 | -- | -12.48 | -8.20 | -38.69 | -- | 63.60 | -- |
BrainCool AB (publ) | 29.15m | -57.05m | 463.71m | 22.00 | -- | 3.82 | -- | 15.91 | -0.2848 | -0.2848 | 0.1465 | 0.4792 | 0.2418 | 2.09 | 3.32 | 1,214,417.00 | -47.34 | -47.14 | -56.18 | -70.16 | -50.61 | -149.77 | -195.75 | -391.45 | 0.7253 | -7.34 | 0.00 | -- | 32.06 | 78.35 | -34.34 | -- | -11.63 | -- |
Bioretec Oy | 45.50m | -44.12m | 618.11m | 37.00 | -- | 6.20 | -- | 13.59 | -0.1984 | -0.1984 | 0.2047 | 0.4213 | 0.5524 | 1.46 | 3.68 | 105,594.60 | -53.58 | -67.11 | -65.75 | -97.60 | 69.85 | 70.97 | -96.98 | -134.05 | 4.86 | -4.02 | 0.0754 | -- | 32.77 | 19.77 | -56.82 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Swedbank Robur Fonder ABas of 29 Feb 2024 | 8.75m | 3.27% |
FCG Fonder ABas of 30 Jun 2022 | 1.64m | 0.61% |
Handelsbanken Fonder ABas of 31 Mar 2024 | 1.50m | 0.56% |
Skandia Investment Management ABas of 29 Feb 2024 | 1.13m | 0.42% |
SEB Investment Management ABas of 28 Mar 2024 | 1.06m | 0.40% |
Storebrand Asset Management ASas of 31 Jan 2024 | 249.49k | 0.09% |
Equinor Asset Management ASAas of 31 Dec 2023 | 54.30k | 0.02% |
Skandia Fonder ABas of 29 Feb 2024 | 43.90k | 0.02% |
Case Kapitalf�rvaltning ABas of 30 Nov 2022 | 18.70k | 0.01% |
Tredje AP-fondenas of 31 Dec 2021 | 0.00 | 0.00% |